NCT05053295Unknown不适用
An Open-label, Single-arm, Single-center, Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo®) in Subjects With Advanced or Recurrent Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR) based on RECIST v1.1
研究概览
简要总结
This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult males and females aged 19 years or above
- •Histologically and/or cytologically confirmed unresectable advanced/relapsed gastric adenocarcinoma or gastro-esophageal junction cancer that meets one of the following criteria:
- •A. Confirmed relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer after at least two prior chemotherapies (Perioperative, neoadjuvant, and adjuvant chemotherapy are not considered as prior chemotherapies, but if the disease progression occurs during or within 6 months of completion of adjuvant chemotherapy, it is considered a prior chemotherapy).
- •B. Patients who are not eligible for standard anti-cancer treatments due to contraindications, intolerance, etc. or who have no other standard treatments available for refusing the treatment may be enrolled at the judgement of the investigator regardless of the number of prior chemotherapies.
- •A measurable lesion based on RECIST v1.1 (Irradiated area will be considered measurable if PD is confirmed in the area).
- •The Eastern Cooperative Oncology Group (ECOG) performance status (PS)0-1
- •Life expectancy of at least 12 weeks
- •Confirmed adequate hematological, hepatic, renal and coagulation functions as follows:
- •A. Hematological function: absolute neutrophil count (ANC) ≥ 1,500/μL, hemoglobin ≥ 9 g/dL, platelet count ≥ 100,000/μL B. Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit normal (ULN), total bilirubin ≤ 1.0 × ULN (if liver metastasis is confirmed, AST/ALT < 3 × ULN) C. Renal function: blood urine nitrogen (BUN) and serum creatinine ≤ 1.5 × ULN D. Blood coagulation:prothrombin time (PT) (international normalized ratio, INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
- •Fully understood the study information (purpose, procedure, etc.) and voluntarily provided a written consent to participate in this study.
排除标准
- •Prior treatment with any cell therapy products including but not limited to Immuncell-LC or natural killer (NK) cell therapy products
- •Prior immuno-oncology agents such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, and anti-CTLA-4
- •Hypersensitivity to the active ingredient or excipients of Immuncell-LC or nivolumab
- •Unable to collect autologous blood for production of Immuncell-LC at the judgement of the investigator
- •History of anti-cancer treatment (chemotherapy, targeted therapy [within 4 weeks for monoclonal antibody], radiation therapy, etc.) within 2 weeks prior to screening
- •An adverse event (AE) with prior treatments that is not resolved (CTCAE grade ≤ 1 or baseline) (with the exceptions of peripheral neuropathy or alopecia that are ≥ grade 2)
- •History of immunosuppressive drugs within 2 weeks prior to screening (with the exceptions of topical, ophthalmic, intra-articular, intranasal, or inhalational corticosteroids, or systemic corticosteroids at doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid)
- •Administration of live vaccines, live attenuated vaccines, or inactivated vaccines within 4 weeks prior to screening
- •The following medical history confirmed at screening: A. Confirmed diagnosis of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) which could worsen by immunotherapy B. History of an active immune disease (e.g. rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, multiple sclerosis, T cell lymphoma) with systemic treatment (disease controllers, corticosteroids, immunosuppressants, etc.) within 2 years prior to screening (Alternative therapies [e.g., thyroxine, insulin, physiologic replacement therapy with corticosteroids for adrenal or pituitary insufficiency] are not considered as systemic treatments) C. History of interstitial lung disease D. Concurrent infection or sepsis E. Evident myocardial failure or uncontrolled arterial hypertension F. Gastrointestinal perforation or fistula G. History of other malignant tumors excluding gastric adenocarcinoma/gastro-esophageal junction cancer within 5 years prior to screening (If the investigator determines that basal cell carcinoma/squamous cell carcinoma of the skin, localized prostate cancer, papillary thyroid carcinoma, or cervical carcinoma in situ is cured after successful treatment, the patients are eligible to participate even if 5 years have not passed)
- •The following concomitant diseases at screening that may affect the safety and efficacy assessments during the study at the judgement of the investigator: A. Clinically significant pericardial effusion, pleural effusion or ascites (e.g., requiring treatment) B. Clinically significant symptoms or uncontrolled central nervous system or brain metastases or carcinomatous meningitis (except if progression is not confirmed clinically and on CT/MRI for at least 4 weeks before administration of the IP and treatment with steroids, etc. is not required for 7 days before administration of the IP after treatment of central nervous system or brain metastases.) C. Diseases that may clinically increase the risk of gastrointestinal bleeding (e.g., active diverticulitis, gastro-intestinal ulcerative disease or disease that can increase the risk of perforation) D. Active hepatitis B (HbsAg positive) or C (The patients are eligible to participate in the study even if HCV antibody is positive as long as RNA is negative, as it will be considered as a prior infection) E. Severe infections or other uncontrolled active infectious diseases requiring administration of antibiotics, antivirals, etc. that may affect the safety and efficacy assessments during the study F. Thromboembolic diseases or bleeding diatheses G. Considered ineligible to participate in the study due to concomitant disease that is uncontrolled or requires treatment (e.g., heart disease, decreased lung function, decreased kidney function, hypotension, hypertension, findings of myelosuppression, hepatitis, liver cirrhosis, history of alcohol addiction, myocardial infarction)
- •Pregnant or breast-feeding women, or women who intend to become pregnant
- •Received other IP or used an investigational device within 4 weeks prior to screening
- •Ineligible or unable to participate in the study at the judgement of the investigator
研究组 & 干预措施
Immuncell-LC/Nivolumab group
Experimental
Patients will receive nivolumab once a day at 4-week intervals and Immuncell-LC 12 times (3 treatments once a week, followed by 5 treatments every other week, and finally 4 treatments every 4 weeks).
干预措施: autologous activated T lymphocyte (Drug)
结局指标
主要结局
Objective response rate (ORR) based on RECIST v1.1
时间窗: Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months after Last Patient In)
ORR is defined as the number of subjects with a best overall response (BOR) of complete response (CR) or partial response (PR) and expressed as a percentage of all treated participants.
次要结局
- DCR based on iRECIST(Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months from the date the last subject was administered))
- Quality of life (QoL) assessment using the EORTC QLQ-STO22(Until end of treatment (Up to approximately 12 months from the date the last subject was administered))
- Progression-free survival (PFS) based on RECIST v1.1(Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months from the date the last subject was administered))
- Disease control rate (DCR) based on RECIST v1.1(Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months from the date the last subject was administered))
- PFS based on iRECIST(Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months from the date the last subject was administered))
- DOR based on iRECIST(Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months from the date the last subject was administered))
- Overall survival (OS)(Until death, follow-up failure or study discontinuation (Up to approximately 12 months after Last Patient In))
- Duration of response (DOR) based on RECIST v1.1(Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months from the date the last subject was administered))
- ORR based on iRECIST(Until disease progression, withdrawn, or initiation of subsequent chemotherapy (Up to approximately 12 months from the date the last subject was administered))
研究者
Jae Yong Cho
Professor
Gangnam Severance Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)NCT06296056Seoul Hospital9
已完成
2 期
Safety and Efficacy of "Immuncell-LC" in TACE TherapyCarcinoma, HepatocellularNCT02856815GC Cell Corporation76
已完成
1 期
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV MelanomaMelanomaNCT00815607Alaunos Therapeutics12
Unknown
2 期
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal CancerMetastatic Colorectal CancerNCT03220984Gangnam Severance Hospital28
已完成
1 期
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCMetastatic Non-small Cell Lung CancerNSCLCNCT03164772Ludwig Institute for Cancer Research61